Soligenix Inc (SNGX) 0.6358 $SNGX
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
PR Newswire - Thu Aug 18, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient dusquetide for treatment of macrophage activation syndrome (MAS). Dusquetide has previously received orphan drug designation for the treatment of acute radiation syndrome (ARS). Dusquetide is an innate defense regulator (IDR), a new class of short, synthetic peptides that accelerates bacterial clearance and resolution of tissue damage while modulating inflammation following exposure to a variety of agents including bacterial pathogens, trauma, radiation and/or chemotherapy.
Soligenix Announces Recent Accomplishments and Second Quarter 2016 Financial Results Highlighted by Revenues of $3.2 Million
PR Newswire - Thu Aug 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the second quarter ended June 30, 2016.
Vista Partners Publishes June 2016 Macroeconomic & Investment Newsletter
Marketwire Canada - Tue Jun 21, 8:01AM CDT
Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Big Data, Biotechnology, Fintech, Healthcare, IoT, SaaS, Sports, WearableTech & More
IBB: 280.89 (-2.40), IMNP: 0.33 (-0.01)
Soligenix Develops Defenses Against Bioterrorism
Marketwire Canada - Thu Jun 16, 8:01AM CDT
SAN FRANCISCO, CA--(Marketwired - June 16, 2016) - Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company.
Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
PR Newswire - Mon Jun 06, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting preliminary results from its SGX942 Phase 2 clinical trial in oral mucositis on June 25, 2016 at the Multinational Association for Supportive Care in Cancer (MASCC) conference taking place in Adelaide, Australia from June 23 to 25, 2016.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.70 (-0.10)
FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis
PR Newswire - Tue May 31, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its SGX943 (dusquetide) development program has received "Fast Track" designation from the US Food and Drug Administration (FDA) as adjunctive therapy with other antibacterial drugs, for the treatment of melioidosis, a serious and potentially life-threatening condition.
Soligenix to Present at the 2016 Marcum MicroCap Conference
PR Newswire - Thu May 26, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2016 Marcum MicroCap Conference on Thursday, June 2, 2016 at 11:30 a.m. EDT. The conference will be held at the Grand Hyatt New York at Park Avenue at Grand Central in New York City. For more information on the conference, please go to http://www.marcumllp.com/MicroCap.
Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
PR Newswire - Wed May 25, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option for the evaluation of RiVax(TM) to fund animal efficacy and toxicology studies. The overall objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax®, combined with the company's ricin toxin vaccine, RiVax(TM), as a medical countermeasure to prevent the effects of ricin exposure.
Soligenix Announces Recent Accomplishments and First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the first quarter ended March 31, 2016.
Soligenix Inc.'s CEO Dr. Christopher Schaber Interviewed by The Life Sciences Report
Marketwired - Thu Apr 28, 8:02AM CDT
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases -- a type of lymphoma and pediatric Crohn's disease -- are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio.
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX)
Marketwired - Tue Apr 19, 8:30AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. ("The Company" or "SNGX"
(OTCBB: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, with a twelve-month price target of $4.50. Ross Silver, Principal Analyst at Vista Partners, stated, "Randal J. Kirk, the CEO of Intrexon which has approximately a $4.3B market cap, has a beneficial ownership position of approximately 20% of Soligenix. In addition, Paolo Cavazza's beneficial ownership position on his own behalf and on behalf of Sigma-Tau is approximately 10% of Soligenix." Mr. Silver concludes, "Soligenix recently reported positive preliminary data from the Phase 2 trial of their clinical candidate SGX942 for the treatment of oral mucositis associated with head & neck cancers. It is estimated that 500,000 patients suffer from oral mucositis, including 40% of patients receiving chemotherapy. On the conference call with investors to discuss the preliminary data of the SGX942 Phase 2 trial, Dr. Christopher Schaber (CEO of Soligenix) stated that he believed the Net Present Value of SGX942 alone was $100M or greater." The market cap of Soligenix on April 18, 2016 was approximately $22M, 4x less than the $100M stated value of SGX942 according to management.
IBB: 280.89 (-2.40)
Soligenix Announces Issuance of New Patents for Dusquetide
PR Newswire - Thu Apr 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Chinese Patent Office intends to grant the patent entitled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity." The newly issued patent claims composition of matter of dusquetide (research name: SGX94) and related analogs. Dusquetide recently demonstrated positive results in a Phase 2 oral mucositis clinical trial. China now becomes the most recent jurisdiction to grant patent coverage over the composition of matter of dusquetide. Similar claims have been granted in the United States, Australia, Israel, Japan, Mexico, New Zealand, Republic of Korea, Russian Federation, Singapore, South Africa and Taiwan. Furthermore, Soligenix is expecting to be granted similar protections in other important jurisdictions, including Europe, in the very near term.
Soligenix Announces Publication of Preclinical Efficacy Results with Dusquetide in Infectious Disease
PR Newswire - Tue Mar 29, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the publication of data demonstrating the mechanism and broad-spectrum activity of dusquetide in preclinical bacterial infection models. Dusquetide, also known by the research name SGX94, is a novel Innate Defense Regulator (IDR) composed of 5 amino acids and is the active ingredient in the lead IDR drug product, SGX942. Recently, SGX942 demonstrated positive results in a Phase 2 clinical trial of oral mucositis in head and neck cancer patients receiving chemoradiation therapy, not only reducing the duration of severe oral mucositis, but also reducing the incidence of infection as well as potentially enhancing the anti-tumor response. The preclinical results were published online in the Journal of Biotechnology and are available at the following link: http://dx.doi.org/10.1016/j.jbiotec.2016.03.032.
Soligenix Announces Recent Accomplishments and Year-End 2015 Financial Results
PR Newswire - Thu Mar 24, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2015.
Soligenix to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
PR Newswire - Tue Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, has been invited to present a company overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016 at 10:45 a.m. EST. The conference will be held at the Convene Conference Center at 730 Third Avenue in New York City. For more information on the conference, please go to www.SourceCapitalConference.com. An audio of the investor presentation can be found on the Soligenix corporate website - www.soligenix.com.
Technical Data and the Price Movement -- Analyst Review of Praxsyn, Baristas Coffee Company, Soligenix and Acacia Diversified Holdings
ACCESSWIRE - Mon Feb 01, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Praxsyn Corp. (OTC: PXYN), Baristas Coffee Company Inc. (OTC: BCCI), Soligenix Inc. (OTC: SNGX) and Acacia Diversified Holdings Inc. (OTC: ACCA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
PR Newswire - Thu Aug 18, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient dusquetide for treatment of macrophage activation syndrome (MAS). Dusquetide has previously received orphan drug designation for the treatment of acute radiation syndrome (ARS). Dusquetide is an innate defense regulator (IDR), a new class of short, synthetic peptides that accelerates bacterial clearance and resolution of tissue damage while modulating inflammation following exposure to a variety of agents including bacterial pathogens, trauma, radiation and/or chemotherapy.
Soligenix Announces Recent Accomplishments and Second Quarter 2016 Financial Results Highlighted by Revenues of $3.2 Million
PR Newswire - Thu Aug 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the second quarter ended June 30, 2016.
Vista Partners Publishes June 2016 Macroeconomic & Investment Newsletter
Marketwire Canada - Tue Jun 21, 8:01AM CDT
Topics Include: Monthly Macroeconomic Commentary, Investment Considerations, Big Data, Biotechnology, Fintech, Healthcare, IoT, SaaS, Sports, WearableTech & More
IBB: 280.89 (-2.40), IMNP: 0.33 (-0.01)
Soligenix Develops Defenses Against Bioterrorism
Marketwire Canada - Thu Jun 16, 8:01AM CDT
SAN FRANCISCO, CA--(Marketwired - June 16, 2016) - Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company.
Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
PR Newswire - Mon Jun 06, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting preliminary results from its SGX942 Phase 2 clinical trial in oral mucositis on June 25, 2016 at the Multinational Association for Supportive Care in Cancer (MASCC) conference taking place in Adelaide, Australia from June 23 to 25, 2016.
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.70 (-0.10)
FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis
PR Newswire - Tue May 31, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its SGX943 (dusquetide) development program has received "Fast Track" designation from the US Food and Drug Administration (FDA) as adjunctive therapy with other antibacterial drugs, for the treatment of melioidosis, a serious and potentially life-threatening condition.
Soligenix to Present at the 2016 Marcum MicroCap Conference
PR Newswire - Thu May 26, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2016 Marcum MicroCap Conference on Thursday, June 2, 2016 at 11:30 a.m. EDT. The conference will be held at the Grand Hyatt New York at Park Avenue at Grand Central in New York City. For more information on the conference, please go to http://www.marcumllp.com/MicroCap.
Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
PR Newswire - Wed May 25, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option for the evaluation of RiVax(TM) to fund animal efficacy and toxicology studies. The overall objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax®, combined with the company's ricin toxin vaccine, RiVax(TM), as a medical countermeasure to prevent the effects of ricin exposure.
Soligenix Announces Recent Accomplishments and First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the first quarter ended March 31, 2016.
Soligenix Inc.'s CEO Dr. Christopher Schaber Interviewed by The Life Sciences Report
Marketwired - Thu Apr 28, 8:02AM CDT
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases -- a type of lymphoma and pediatric Crohn's disease -- are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio.
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX)
Marketwired - Tue Apr 19, 8:30AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. ("The Company" or "SNGX"
(OTCBB: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, with a twelve-month price target of $4.50. Ross Silver, Principal Analyst at Vista Partners, stated, "Randal J. Kirk, the CEO of Intrexon which has approximately a $4.3B market cap, has a beneficial ownership position of approximately 20% of Soligenix. In addition, Paolo Cavazza's beneficial ownership position on his own behalf and on behalf of Sigma-Tau is approximately 10% of Soligenix." Mr. Silver concludes, "Soligenix recently reported positive preliminary data from the Phase 2 trial of their clinical candidate SGX942 for the treatment of oral mucositis associated with head & neck cancers. It is estimated that 500,000 patients suffer from oral mucositis, including 40% of patients receiving chemotherapy. On the conference call with investors to discuss the preliminary data of the SGX942 Phase 2 trial, Dr. Christopher Schaber (CEO of Soligenix) stated that he believed the Net Present Value of SGX942 alone was $100M or greater." The market cap of Soligenix on April 18, 2016 was approximately $22M, 4x less than the $100M stated value of SGX942 according to management. IBB: 280.89 (-2.40)
Soligenix Announces Issuance of New Patents for Dusquetide
PR Newswire - Thu Apr 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Chinese Patent Office intends to grant the patent entitled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity." The newly issued patent claims composition of matter of dusquetide (research name: SGX94) and related analogs. Dusquetide recently demonstrated positive results in a Phase 2 oral mucositis clinical trial. China now becomes the most recent jurisdiction to grant patent coverage over the composition of matter of dusquetide. Similar claims have been granted in the United States, Australia, Israel, Japan, Mexico, New Zealand, Republic of Korea, Russian Federation, Singapore, South Africa and Taiwan. Furthermore, Soligenix is expecting to be granted similar protections in other important jurisdictions, including Europe, in the very near term.
Soligenix Announces Publication of Preclinical Efficacy Results with Dusquetide in Infectious Disease
PR Newswire - Tue Mar 29, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the publication of data demonstrating the mechanism and broad-spectrum activity of dusquetide in preclinical bacterial infection models. Dusquetide, also known by the research name SGX94, is a novel Innate Defense Regulator (IDR) composed of 5 amino acids and is the active ingredient in the lead IDR drug product, SGX942. Recently, SGX942 demonstrated positive results in a Phase 2 clinical trial of oral mucositis in head and neck cancer patients receiving chemoradiation therapy, not only reducing the duration of severe oral mucositis, but also reducing the incidence of infection as well as potentially enhancing the anti-tumor response. The preclinical results were published online in the Journal of Biotechnology and are available at the following link: http://dx.doi.org/10.1016/j.jbiotec.2016.03.032.
Soligenix Announces Recent Accomplishments and Year-End 2015 Financial Results
PR Newswire - Thu Mar 24, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2015.
Soligenix to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
PR Newswire - Tue Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, PhD, President and Chief Executive Officer, has been invited to present a company overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016 at 10:45 a.m. EST. The conference will be held at the Convene Conference Center at 730 Third Avenue in New York City. For more information on the conference, please go to www.SourceCapitalConference.com. An audio of the investor presentation can be found on the Soligenix corporate website - www.soligenix.com.
Technical Data and the Price Movement -- Analyst Review of Praxsyn, Baristas Coffee Company, Soligenix and Acacia Diversified Holdings
ACCESSWIRE - Mon Feb 01, 8:20AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Praxsyn Corp. (OTC: PXYN), Baristas Coffee Company Inc. (OTC: BCCI), Soligenix Inc. (OTC: SNGX) and Acacia Diversified Holdings Inc. (OTC: ACCA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
